Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2360-2368

  Lo Re, Vincent ^a,b   Haynes, Kevin ^b   Forde, Kimberly A ^a,b   Goldberg, David S ^a,b   Lewis, James D ^a,b   Carbonari, Dena M ^b   Leidl, Kimberly B F ^b   Reddy, K Rajender ^a,b   Nezamzadeh, Melissa S ^b   Roy, Jason ^b   Sha, Daohang ^b   Marks, Amy R ^c   De Boer, Jolanda ^c   Schneider, Jennifer L ^c   Strom, Brian L ^b,d   Corley, Douglas A ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Acute liver failure; DILI; Drug induced liver injury; Hepatotoxicity; Hy's law

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; AMINOTRANSFERASE;

ACUTE LIVER FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL EVALUATION; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS; BLOOD; CALIFORNIA; CHEMICALLY INDUCED; COMPLICATION; DECISION SUPPORT SYSTEM; LIVER FAILURE, ACUTE; MIDDLE AGED; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; CALIFORNIA; CHEMICAL AND DRUG INDUCED LIVER INJURY; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSAMINASES; YOUNG ADULT;

EID: 84947431416     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.06.020     Document Type: Article

References (23)

1. Friis H., Andreasen P.B. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992, 232:133-138.
2. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934. 1934 e1-4.
3. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001, 24:483-490.
4. Zimmerman H.J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver 1999, Lippincott, Philadelphia.
5. Reuben A. Hy's law. Hepatology 2004, 39:574-578.
6. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006, 15:241-243.
7. Friedman G., Habel L., Boles M., et al. Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division. Pharmacoepidemiology 2000, 263-283. John Wiley & Sons, Ltd., West Sussex. 3rd ed. B.L. Strom (Ed.).
8. Fontana R.J. Acute liver failure due to drugs. Semin Liver Dis 2008, 28:175-187.
9. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89:806-815.
10. Polson J., Lee W.M. AASLD position paper: the management of acute liver failure. Hepatology 2005, 41:1179-1197.
11. Goldberg D.S., Forde K.A., Carbonari D.M., et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology 2015, 148:1353-1361.
12. Lo Re V., Carbonari D.M., Forde K.A., et al. Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf 2015, 24:676-683.
13. Reuben A., Koch D.G., Lee W.M. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
14. Robles-Diaz M., Lucena M.I., Kaplowitz N., et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014, 147:109-118 e5.
15. Jeong R., Lee Y.S., Sohn C., et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury. Scand J Gastroenterol 2015, 50:439-446.
16. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
17. Peduzzi P., Concato J., Kemper E., et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996, 49:1373-1379.
18. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387.
19. Lee W.M., Hynan L.S., Rossaro L., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137:856-864. 864 e1.
20. Bateman D.N., Dear J.W., Thanacoody H.K., et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet 2014, 383:697-704.
21. Fontana R.J., Hayashi P.H., Gu J., et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014, 147:96-108 e4.
22. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
23. Bjornsson E.S., Bergmann O.M., Bjornsson H.K., et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144:1419-1425. 1425 e1-3; quiz e19-20.